Trial Profile
The Special Drug Use-results Survey (All-Case Surveillance) of Ofev Capsules in Patients With Idiopathic Pulmonary Fibrosis (IPF) in Japan
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Nov 2023
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 23 Nov 2023 Status changed from recruiting to completed.
- 12 Oct 2023 Planned End Date changed from 30 Sep 2023 to 30 Nov 2023.
- 12 Oct 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Nov 2023.